Healthcare Professional Portal
Healthcare Professional Portal
12 CPD hours.
The British Menopause Society’s 35th Annual Scientific Conference returns on 25–26 June 2026 at Chesford Grange, Kenilworth, bringing together academics, GPs, gynaecologists, specialist nurses, pharmacists, and allied health professionals for a two-day in-person event open to all healthcare professionals with an interest in post-reproductive health, from the UK and overseas.
The programme covers the latest developments across menopause care, under the theme: The Menopause Landscape: Pathways to Better Care.
Offering 12 CPD hours, the programme provides a focused opportunity to review current evidence, hear from leading specialists, and strengthen connections across the menopause and women’s health community.
Register today – open to all eligible healthcare professionals!
Click the button below to be redirected to the congress website to find out more:
One of our product specialists would be happy to answer your questions.
QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
References
1 – QUVIVIQ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
1 – QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics.
2 – Roch C, et al. Psychopharmacology. 2021; 238(10): 2693–2708.
3 – NICE Clinical Knowledge Summary (CKS) Insomnia: Scenario: Managing long-term insomnia (more than 3 months duration). Available at: https://cks.nice.org.uk/topics/insomnia/management/managing-insomnia/. Updated June 2024. Accessed July 2024.
4 – Mignot E, et al. Lancet Neurol. 2022; 21(2): 125–139.
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google play or Apple App store. Adverse events should also be reported to ds.safety.uk@idorsia.com.
You are being redirected to our partner’s website pro.idorsia.uk.
The content of this website contains promotional information for UK healthcare professionals and is managed by Idorsia Pharmaceuticals UK Ltd.
UK-DA-01463 | Date of preparation: April 2026
Your resource is ready to download.
Providing your details is optional, but enables us to share future updates and resources that may be of interest to you.
Download will open in a new window.
Register and stay up to date with the latest news about QUVIVIQ™▼ (daridorexant), chronic insomnia and sleep science. By registering and ticking this box you are confirming you have read and agreed to the Informed Consent and Privacy Policy and you herewith consent to the processing of your personal data in line therewith.
You are now leaving pro.idorsia.uk. You will now be redirected to an independent third-party site that is maintained outside of this website.
You are now leaving pro.idorsia.uk. The linked website provides helpful information if you are having trouble sleeping. It is neither owned or controlled by Idorsia Pharmaceuticals Ltd. Idorsia accepts no responsibility for the content or services of the linked site.
UK-DA-00445 | Date of preparation: Februrary 2026
Confirming your contact information and preferences means that you agree that we, Idorsia, manage your personal data in our Client Relationship Management system to document, customise, plan, and conduct our interactions with you and, to analyse and segment your interactions, interests, preferences, and scientific activities in order to interact with you in a way we think is most relevant to you.
It also means that you agree that we will send you Idorsia standard or personalised medical, company or product related information and material via email based on your choices and on what we think is of interest to you. You further consent that we process your personal data for this.
For more information about us, our processing of your personal data and your rights, please see our Privacy Notice.
You already have an account?
Register to get access to:
